Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

Saved in:
Bibliographic Details
Title: Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.
Authors: Van Den Blink B; Kinevant Sciences, Inc., New York, NY, USA., Birring SS; Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK., Mogulkoc N; Department of Chest Diseases, University of Ege, Izmir, Turkey., Nayci Atis S; Department of Pulmonology, University of Mersin, Mersin, Turkey., Gupta R; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA., Guiot J; Department of Respiratory Medicine, CHU Liège, Liège, Belgium., Hart SP; Respiratory Research Group, Hull York Medical School/University of Hull, Cottingham, UK., Carmona Porquera EM; Department of Pulmonary Medicine, Mayo Clinic, Rochester, MN, USA., Koeller HB; Kinevant Sciences, Inc., New York, NY, USA., Arocho N; Kinevant Sciences, Inc., New York, NY, USA., Petit CM; Kinevant Sciences, Inc., New York, NY, USA., Denning J; Kinevant Sciences, Inc., New York, NY, USA., Lin M; Roivant Sciences, Inc., New York, NY, USA., Baughman RP; Department of Medicine, University of Cincinnati, Cincinnati, OH, USA., Wijsenbeek-Lourens M; Center for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Reiss TF; Kinevant Sciences, Inc., New York, NY, USA ted.reiss@roivant.com.
Corporate Authors: RESOLVE-Lung investigators
Source: The European respiratory journal [Eur Respir J] 2026 Jul 09; Vol. 68 (1). Date of Electronic Publication: 2026 Jul 09 (Print Publication: 2026).
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1399-3003
DOI:10.1183/13993003.01874-2025